INCB 50465

Drug Profile

INCB 50465

Alternative Names: INCB-050465; INCB-50465

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Myelofibrosis
  • Phase I/II B cell lymphoma; Solid tumours

Most Recent Events

  • 25 Oct 2017 Incyte Corporation plans the phase I CITADEL-111 trial for B-cell lymphoma (Second-line therapy or greater) in June 2018 (NCT03314922)
  • 05 Oct 2017 Phase-II clinical trials in Mantle cell lymphoma (Refractory metastatic disease, Second-line therapy or greater, Recurrent) in USA (unspecified route)
  • 04 Aug 2017 Incyte plans a phase II trial for Mantle cell lymphoma (Second-line therapy or greater, Refractory metastatic disease) (NCT03235544)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top